Radiation Biology

This is an experimental radio-immunotherapy program comprised of 5 highly interactive laboratories using radiolabeled antibodies that bind to antigens expressed on the surface of cancer cells.



The Division of Radiation Biology was established by the Comprehensive Cancer Center and the Department of Radiation Oncology in October 1990. Donald J. Buchsbaum, PhD, was recruited as Division Director. The Division has developed innovative approaches to radioimmunotherapy of cancer using novel targeting molecules and has been in the forefront of research into the treatment of cancer in experimental models with a combination of gene therapy and radiation therapy.

The Division has developed innovative approaches to radioimmunotherapy of cancer using novel targeting molecules.  This research has contributed to the funding of Ovarian and Breast Cancer Specialized Programs of Research Excellence (SPORE) at UAB by the National Cancer Institute, and funding to the Cancer Center from the Avon Products Research Foundation for breast cancer research.  In addition, the Division of Radiation Biology has been in the forefront of research into the treatment of cancer in experimental models with a combination of gene therapy and radiation therapy.  This has resulted in a SPORE in Brain Cancer and grants and contracts from the National Cancer Institute, the Department of Energy, and the Department of Defense, with emphasis on colon, ovarian, and prostate cancer.  Another significant finding was that unlabeled antibody against epidermal growth factor receptor resulted in increased sensitivity of head and neck cancer to radiation.  This was translated into a clinical phase I trial in head and neck cancer at UAB.  A phase III trial testing this new combination therapy with UAB as the lead institution showed significantly increased local tumor control and survival in patients with head and neck cancer.  This resulted in FDA approval of this therapy for patients with head and neck cancer.

The Division has also played a central role in the evaluation of death receptor antibodies for cancer therapy, and has received support for this research from Daiichi Sankyo through the UAB/Sankyo Program for Rheumatic Diseases and Cancer Research in the Arthritis and Musculoskeletal Diseases Center, and from the Pancreatic Cancer SPORE and Accelerated Brain Cancer Cure, Inc.


Radiation Biology Team